diff --git "a/dev_JRCT_api/vector_searchE2.ipynb" "b/dev_JRCT_api/vector_searchE2.ipynb"
new file mode 100644--- /dev/null
+++ "b/dev_JRCT_api/vector_searchE2.ipynb"
@@ -0,0 +1,2758 @@
+{
+ "cells": [
+  {
+   "cell_type": "code",
+   "execution_count": 1,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/sentence_transformers/cross_encoder/CrossEncoder.py:13: TqdmExperimentalWarning: Using `tqdm.autonotebook.tqdm` in notebook mode. Use `tqdm.tqdm` instead to force console mode (e.g. in jupyter console)\n",
+      "  from tqdm.autonotebook import tqdm, trange\n"
+     ]
+    }
+   ],
+   "source": [
+    "from sentence_transformers import SentenceTransformer, util\n",
+    "import pandas as pd\n",
+    "import re"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 76,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# Target列を分割する関数\n",
+    "def split_target(target):\n",
+    "    # 指定された区切り文字で分割\n",
+    "    split_words = re.split(r'[,\\n、・及びおよび又はまたは]+', target)\n",
+    "    # 空白文字を除外してリストとして返す\n",
+    "    return [word.strip() for word in split_words if word.strip()]\n",
+    "\n",
+    "\n",
+    "# Target列を分割する関数（改良後）\n",
+    "def split_target_English(target):\n",
+    "    # 区切り文字を (,) or (\\n) or (、) or (・) または文字列\"or\" として扱う\n",
+    "    # 正規表現では、パイプ(|)でor条件を定義し、\"(?: ... )\"はグルーピングのみ行う非捕捉グループ\n",
+    "    # [,\\n、・] はいずれかの1文字とマッチ\n",
+    "    # or は文字列全体とマッチ\n",
+    "    # 複数連続した区切り文字をまとめて1回の分割として扱うために+(1回以上)とする\n",
+    "    split_words = re.split(r'(?:[,\\n、・]|or| and)+', target)\n",
+    "    \n",
+    "    # 空白文字を除外してリストとして返す\n",
+    "    return [word.strip() for word in split_words if word.strip()]\n",
+    "\n",
+    "# 処理プログラム\n",
+    "def split_triple_negative_words(target_words):\n",
+    "    updated_words = []\n",
+    "    for word in target_words:\n",
+    "        if 'triple negative' in word.lower():\n",
+    "            # 'triple negative' の部分を追加\n",
+    "            updated_words.append('Triple Negative')  # 大文字で統一して追加\n",
+    "            # 'triple negative' を除いた残りの部分を追加\n",
+    "            remaining = word.lower().replace('triple negative', '').strip()\n",
+    "            if remaining:  # 残りの単語が存在する場合のみ追加\n",
+    "                updated_words.append(remaining.title().strip())  # 単語の先頭を大文字化\n",
+    "        else:\n",
+    "            updated_words.append(word.strip().title())  # 単語の先頭を大文字化\n",
+    "    return updated_words\n",
+    "\n",
+    "class WordProcessor:\n",
+    "    def __init__(self, target_words):\n",
+    "        self.target_words = target_words\n",
+    "\n",
+    "    def process(self, target_words):\n",
+    "        \"\"\"\n",
+    "        入力された単語のリストを処理して、ターゲット単語に基づき分割します。\n",
+    "        \"\"\"\n",
+    "        updated_words = []\n",
+    "        for word in target_words:\n",
+    "            word_lower = word.lower()\n",
+    "            for target in self.target_words:\n",
+    "                if target in word_lower:\n",
+    "                    # ターゲット単語を追加\n",
+    "                    updated_words.append(target.title())\n",
+    "                    # ターゲット単語を除いた残りを追加\n",
+    "                    remaining = word_lower.replace(target, '').strip()\n",
+    "                    if remaining:\n",
+    "                        updated_words.append(remaining.title())\n",
+    "                    break\n",
+    "            else:\n",
+    "                # ターゲット単語に該当しない場合\n",
+    "                updated_words.append(word.strip().title())\n",
+    "        return updated_words\n",
+    "\n",
+    "    def __call__(self, target_words):\n",
+    "        \"\"\"\n",
+    "        インスタンスを関数として呼び出すためのエントリポイント。\n",
+    "        \"\"\"\n",
+    "        return self.process(target_words)\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 77,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "exclusive_words = [\"triple negative\", \"double positive\"]\n",
+    "\n",
+    "    # インスタンス作成\n",
+    "processor = WordProcessor(exclusive_words)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 78,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "basedf = pd.read_csv('../ClinicalTrialCSV/JRCT20241215Cancer.csv', index_col=0)\n",
+    "basedf = basedf.dropna(subset=['試験等のフェーズ'])\n",
+    "# Target列を分割してTargetWord列を追加\n",
+    "basedf['TargetWord'] = basedf['TargetEnglish'].apply(split_target_English)\n",
+    "# 各行のTargetWord列に処理を適用\n",
+    "# NaN や None の場合の処理を追加\n",
+    "basedf['TargetWord'] = basedf['TargetWord'].apply(lambda x: processor(x) if isinstance(x, list) else x)"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 79,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>0</th>\n",
+       "      <td>jRCT2031240552</td>\n",
+       "      <td>NCT06599502</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...</td>\n",
+       "      <td>以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌</td>\n",
+       "      <td>以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌</td>\n",
+       "      <td>Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be 18 years or more, or th...</td>\n",
+       "      <td>1. Any significant laboratory finding or any s...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>AZD0022</td>\n",
+       "      <td>[Non-Small Cell Lung Cancer (Nsclc) Pancreatic...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>3</th>\n",
+       "      <td>jRCT2031240547</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...</td>\n",
+       "      <td>切除不能進行・再発の胃または食道胃接合部腺癌</td>\n",
+       "      <td>切除不能進行・再発の胃または食道胃接合部腺癌</td>\n",
+       "      <td>Advanced Gastric or Gastroesophageal Junction ...</td>\n",
+       "      <td>フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1) Histologically documented gastric or GEJ ad...</td>\n",
+       "      <td>1) Prior treatment with taxanes 2) Prior treat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Bemarituzumab (15mg/kg, intravenous, Day1, 1...</td>\n",
+       "      <td>[Advanced Gastric, Gastroesophageal Junction C...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>5</th>\n",
+       "      <td>jRCT2031240542</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...</td>\n",
+       "      <td>多発性骨髄腫</td>\n",
+       "      <td>多発性骨髄腫</td>\n",
+       "      <td>Multiple Myeloma</td>\n",
+       "      <td>自家造血幹細胞移植非適��の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Is at least 18 or the legal age of consent ...</td>\n",
+       "      <td>Participants are excluded from the study if an...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm A: Belantamab Mafodotin is intraveniously ...</td>\n",
+       "      <td>[Multiple Myeloma]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>7</th>\n",
+       "      <td>jRCT2031240536</td>\n",
+       "      <td>NCT06003231</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...</td>\n",
+       "      <td>頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>Head and neck squamous cell carcinoma/Non-smal...</td>\n",
+       "      <td>既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Cohort 1: Head and neck squamous cell carcinom...</td>\n",
+       "      <td>- Prior treatment with a monomethyl auristatin...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental Arm - Disitamab vedotin 1.5 mg/kg...</td>\n",
+       "      <td>[Head, Neck Squamous Cell Carcinoma/Non-Small ...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>9</th>\n",
+       "      <td>jRCT2031240530</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
+       "      <td>Stage II-III HER2-Amplified or HER2-Mutant Non...</td>\n",
+       "      <td>HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Signed informed consent form 2. Age &gt;= 18 y...</td>\n",
+       "      <td>1. NSCLC that is clinically T4 by virtue of me...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The study drug will be administered as an IV i...</td>\n",
+       "      <td>[Stage Ii-Iii Her2-Amplified, Her2-Mutant Non-...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>...</th>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "      <td>...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>739</th>\n",
+       "      <td>jRCT2073200004</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験</td>\n",
+       "      <td>膵癌</td>\n",
+       "      <td>膵癌</td>\n",
+       "      <td>Pancreatic cancer</td>\n",
+       "      <td>切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>The patients with pancreatic tumors must meet ...</td>\n",
+       "      <td>1) Patients with the following complications: ...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Pancreatic ductal carcinoma, unresectable</td>\n",
+       "      <td>Intratumoral administration of oncolytic virus</td>\n",
+       "      <td>[Pancreatic Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>760</th>\n",
+       "      <td>jRCT2033190086</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...</td>\n",
+       "      <td>悪性黒色腫</td>\n",
+       "      <td>悪性黒色腫</td>\n",
+       "      <td>malignant melanoma</td>\n",
+       "      <td>第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>(Phase 1) 1) Histologically confirmed malignan...</td>\n",
+       "      <td>(Phase 1 and 2) 1) Patients who have brain and...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>malignamt melanoma, advanced stage</td>\n",
+       "      <td>Test drug (T-hIL12) will be administered into ...</td>\n",
+       "      <td>[Malignant Melanoma]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>762</th>\n",
+       "      <td>jRCT2031190072</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験</td>\n",
+       "      <td>肝細胞癌</td>\n",
+       "      <td>肝細胞癌</td>\n",
+       "      <td>Hepatocellular carcinoma</td>\n",
+       "      <td>切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1) Histologically or cytologically confirmed h...</td>\n",
+       "      <td>1) CNS metastases that are symptomatic or requ...</td>\n",
+       "      <td>20age 0month 0week old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Cancer peptide vaccine</td>\n",
+       "      <td>Reconstitute two kinds of cancer peptide vacci...</td>\n",
+       "      <td>[Hepatocellular Carcinoma]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>772</th>\n",
+       "      <td>jRCT2051190009</td>\n",
+       "      <td>NCT03818893</td>\n",
+       "      <td>JapicCTI-194618</td>\n",
+       "      <td>進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...</td>\n",
+       "      <td>進行性悪性黒色腫</td>\n",
+       "      <td>進行性悪性黒色腫</td>\n",
+       "      <td>advanced melanoma</td>\n",
+       "      <td>抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Inclusion criteria Patients meeting all of the...</td>\n",
+       "      <td>Exclusion criteria Patients meeting any of the...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>86age old not</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>advanced melanoma</td>\n",
+       "      <td>combination therapy of intracutaneous GEN0101 ...</td>\n",
+       "      <td>[Advanced Melanoma]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>427 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No      JapicCTI No  \\\n",
+       "0    jRCT2031240552  NCT06599502              NaN   \n",
+       "3    jRCT2031240547          NaN              NaN   \n",
+       "5    jRCT2031240542          NaN              NaN   \n",
+       "7    jRCT2031240536  NCT06003231              NaN   \n",
+       "9    jRCT2031240530          NaN              NaN   \n",
+       "..              ...          ...              ...   \n",
+       "729  jRCT2031200057          NaN              NaN   \n",
+       "739  jRCT2073200004          NaN              NaN   \n",
+       "760  jRCT2033190086          NaN              NaN   \n",
+       "762  jRCT2031190072          NaN              NaN   \n",
+       "772  jRCT2051190009  NCT03818893  JapicCTI-194618   \n",
+       "\n",
+       "                                                 Title  \\\n",
+       "0    KRAS G12D 変異陽性がん患者を対象としてAZD0022 の単剤療法及び抗がん剤との併...   \n",
+       "3    FGFR2b陽性切除不能進行・再発の胃または食道胃接合部腺癌を対象としたBemarituzu...   \n",
+       "5    自家造血幹細胞移植非適応の初発多発性骨髄腫患者を対象としてベランタマブ マホドチンとレナリド...   \n",
+       "7    既治療の局所進行切除不能又は転移性HER2発現固形癌を有する成人患者を対象としたDisita...   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII-III期非小細胞肺癌に対するTra...   \n",
+       "..                                                 ...   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験   \n",
+       "739            切除不能膵癌を対象とした腫瘍溶解性ウイルスの腫瘍内局所投与の臨床第Ⅰ/Ⅱ相試験   \n",
+       "760  悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...   \n",
+       "762                  切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験   \n",
+       "772  進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...   \n",
+       "\n",
+       "                                               TargetJ  \\\n",
+       "0                 以下の進行固形がん患者\\n・非小細胞肺癌\\n・膵管腺癌\\n・結腸・直腸癌   \n",
+       "3                               切除不能進行・再発の胃または食道胃接合部腺癌   \n",
+       "5                                               多発性骨髄腫   \n",
+       "7                            頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...   \n",
+       "..                                                 ...   \n",
+       "729                                                乳がん   \n",
+       "739                                                 膵癌   \n",
+       "760                                              悪性黒色腫   \n",
+       "762                                               肝細胞癌   \n",
+       "772                                           進行性悪性黒色腫   \n",
+       "\n",
+       "                                                Target  \\\n",
+       "0                    以下の進行固形がん患者 ・非小細胞肺癌 ・膵管腺癌 ・結腸・直腸癌   \n",
+       "3                               切除不能進行・再発の胃または食道胃接合部腺癌   \n",
+       "5                                               多発性骨髄腫   \n",
+       "7                            頭頸部扁平上皮癌、非小細胞肺癌、卵巣癌、子宮内膜癌   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...   \n",
+       "..                                                 ...   \n",
+       "729                                                乳がん   \n",
+       "739                                                 膵癌   \n",
+       "760                                              悪性黒色腫   \n",
+       "762                                               肝細胞癌   \n",
+       "772                                           進行性悪性黒色腫   \n",
+       "\n",
+       "                                         TargetEnglish  \\\n",
+       "0    Non-Small Cell Lung Cancer (NSCLC) Pancreatic ...   \n",
+       "3    Advanced Gastric or Gastroesophageal Junction ...   \n",
+       "5                                     Multiple Myeloma   \n",
+       "7    Head and neck squamous cell carcinoma/Non-smal...   \n",
+       "9    Stage II-III HER2-Amplified or HER2-Mutant Non...   \n",
+       "..                                                 ...   \n",
+       "729                                      Breast cancer   \n",
+       "739                                  Pancreatic cancer   \n",
+       "760                                 malignant melanoma   \n",
+       "762                           Hepatocellular carcinoma   \n",
+       "772                                  advanced melanoma   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "0                                            Treatment      1-2   NaN  ...   \n",
+       "3    フッ化ピリミジン系薬剤に不応または不耐となったFGFR2b陽性の切除不能進行・再発の胃腺癌又...        2   NaN  ...   \n",
+       "5    自家造血幹細胞移植非適応の初発多発性骨髄腫を対象にGSK2857916、レナリドミド 及び ...        3   NaN  ...   \n",
+       "7    既治療の局所進行切除不能又は転移性(LA/m)ヒト上皮増殖因子受容体2型(HER2)発現固形...        2   NaN  ...   \n",
+       "9    HER2遺伝子増幅あるいはHER2遺伝子変異を有するII/IIIA/IIIB(T3-4N2)...        2   NaN  ...   \n",
+       "..                                                 ...      ...   ...  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "739      切除不能膵癌患者に対するSurv.m-CRA-1の腫瘍内投与の安全性及び有効性を検討する。      1-2   NaN  ...   \n",
+       "760  第I相パート:進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...      1-2   NaN  ...   \n",
+       "762                  切除不能な進行肝細胞癌患者を対象としたCYT001の第I相臨床試験        1   NaN  ...   \n",
+       "772  抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...      1-2   NaN  ...   \n",
+       "\n",
+       "               purpose                                 Inclusion Criteria  \\\n",
+       "0    treatment purpose  1. Participant must be 18 years or more, or th...   \n",
+       "3    treatment purpose  1) Histologically documented gastric or GEJ ad...   \n",
+       "5    treatment purpose  1. Is at least 18 or the legal age of consent ...   \n",
+       "7    treatment purpose  Cohort 1: Head and neck squamous cell carcinom...   \n",
+       "9    treatment purpose  1. Signed informed consent form 2. Age >= 18 y...   \n",
+       "..                 ...                                                ...   \n",
+       "729  treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "739  treatment purpose  The patients with pancreatic tumors must meet ...   \n",
+       "760  treatment purpose  (Phase 1) 1) Histologically confirmed malignan...   \n",
+       "762  treatment purpose  1) Histologically or cytologically confirmed h...   \n",
+       "772  treatment purpose  Inclusion criteria Patients meeting all of the...   \n",
+       "\n",
+       "                                    Exclusion Criteria  \\\n",
+       "0    1. Any significant laboratory finding or any s...   \n",
+       "3    1) Prior treatment with taxanes 2) Prior treat...   \n",
+       "5    Participants are excluded from the study if an...   \n",
+       "7    - Prior treatment with a monomethyl auristatin...   \n",
+       "9    1. NSCLC that is clinically T4 by virtue of me...   \n",
+       "..                                                 ...   \n",
+       "729  1)Patients correspond to either of the followi...   \n",
+       "739  1) Patients with the following complications: ...   \n",
+       "760  (Phase 1 and 2) 1) Patients who have brain and...   \n",
+       "762  1) CNS metastases that are symptomatic or requ...   \n",
+       "772  Exclusion criteria Patients meeting any of the...   \n",
+       "\n",
+       "                     Age Minimum    Age Maximum  Gender  \\\n",
+       "0                 18age old over       No limit    Both   \n",
+       "3                 18age old over       No limit    Both   \n",
+       "5                 18age old over       No limit    Both   \n",
+       "7                 18age old over       No limit    Both   \n",
+       "9                 18age old over       No limit    Both   \n",
+       "..                           ...            ...     ...   \n",
+       "729               20age old over       No limit  Female   \n",
+       "739               20age old over       No limit    Both   \n",
+       "760               20age old over       No limit    Both   \n",
+       "762  20age 0month 0week old over       No limit    Both   \n",
+       "772               20age old over  86age old not    Both   \n",
+       "\n",
+       "    Discontinuation Criteria                                    Keyword  \\\n",
+       "0                        NaN                                        NaN   \n",
+       "3                        NaN                                        NaN   \n",
+       "5                        NaN                                        NaN   \n",
+       "7                        NaN                                        NaN   \n",
+       "9                        NaN                                        NaN   \n",
+       "..                       ...                                        ...   \n",
+       "729                      NaN                              Breast cancer   \n",
+       "739                      NaN  Pancreatic ductal carcinoma, unresectable   \n",
+       "760                      NaN         malignamt melanoma, advanced stage   \n",
+       "762                      NaN                     Cancer peptide vaccine   \n",
+       "772                      NaN                          advanced melanoma   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "0                                              AZD0022   \n",
+       "3    - Bemarituzumab (15mg/kg, intravenous, Day1, 1...   \n",
+       "5    Arm A: Belantamab Mafodotin is intraveniously ...   \n",
+       "7    Experimental Arm - Disitamab vedotin 1.5 mg/kg...   \n",
+       "9    The study drug will be administered as an IV i...   \n",
+       "..                                                 ...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "739     Intratumoral administration of oncolytic virus   \n",
+       "760  Test drug (T-hIL12) will be administered into ...   \n",
+       "762  Reconstitute two kinds of cancer peptide vacci...   \n",
+       "772  combination therapy of intracutaneous GEN0101 ...   \n",
+       "\n",
+       "                                            TargetWord  \n",
+       "0    [Non-Small Cell Lung Cancer (Nsclc) Pancreatic...  \n",
+       "3    [Advanced Gastric, Gastroesophageal Junction C...  \n",
+       "5                                   [Multiple Myeloma]  \n",
+       "7    [Head, Neck Squamous Cell Carcinoma/Non-Small ...  \n",
+       "9    [Stage Ii-Iii Her2-Amplified, Her2-Mutant Non-...  \n",
+       "..                                                 ...  \n",
+       "729                                    [Breast Cancer]  \n",
+       "739                                [Pancreatic Cancer]  \n",
+       "760                               [Malignant Melanoma]  \n",
+       "762                         [Hepatocellular Carcinoma]  \n",
+       "772                                [Advanced Melanoma]  \n",
+       "\n",
+       "[427 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 79,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "basedf.dropna(subset=['TargetEnglish'])"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 80,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "391    [Relapsed/Refract, Y Locally Advanced, Metasta...\n",
+      "Name: TargetWord, dtype: object\n",
+      "391    Relapsed/Refractory Locally Advanced or Metast...\n",
+      "Name: TargetEnglish, dtype: object\n",
+      "391    Dose Escalation and Expansion Cohorts 1. Women...\n",
+      "Name: Exclusion Criteria, dtype: object\n"
+     ]
+    }
+   ],
+   "source": [
+    "print(basedf[basedf['JRCT ID'] == 'jRCT2031230090']['TargetWord'])\n",
+    "print(basedf[basedf['JRCT ID'] == 'jRCT2031230090']['TargetEnglish'])\n",
+    "print(basedf[basedf['JRCT ID'] == 'jRCT2031230090']['Exclusion Criteria'])"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 81,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stdout",
+     "output_type": "stream",
+     "text": [
+      "['Relapsed/Refract', 'Y Locally Advanced', 'Metastatic Breast Cancer', 'Triple Negative', 'Breast Cancer']\n",
+      "Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer\n",
+      "Dose Escalation and Expansion Cohorts 1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) not using adequate birth control see Appendix H: Forms of contraception. 2. Patients with known central nervous system (CNS) or leptomeningeal metastases not controlled by prior surgery, radiotherapy or requiring corticosteroids to control symptoms, or patients with symptoms suggesting CNS involvement for which treatment is required. 3. Patients with primary brain tumors. 4. Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma. 5. Patients with any of the following hematologic abnormalities at baseline. (Patients may have received a red blood cell product transfusion prior to study, if clinically warranted.): -Absolute neutrophil count (ANC) < 1,500 per mm3 -Platelet count < 100,000 per mm3 -Hemoglobin < 8.0 gm/dL 6. Patients with any of the following serum chemistry abnormalities at baseline: -Total bilirubin >= 1.5 times the ULN for the institution value -AST or ALT >= 3 times the ULN for the institution value (>= 5 times if due to hepatic involvement by tumor) -Creatinine >= 1.5 times ULN for the institution value (or a calculated creatinine clearance < 60 mL/min/1.73 m2) 7. Patients with a significant active cardiovascular disease or condition, including: -Congestive heart failure (CHF)requiring therapy -Need for antiarrhythmic medical therapy for a ventricular arrhythmia -Severe conduction disturbance -Unstable angina pectoris requiring therapy -QTc interval > 450 msec (males) or > 470 msec (females) -QTc interval =< 300 msec -History of congenital long QT syndrome or congenital short QT syndrome -LVEF < 50% as measured by echocardiography or MUGA scan -Uncontrolled hypertension (per the Investigator's discretion) -Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria (see APPENDIX C: New York Heart Association's Functional Criteria). -Myocardial infarction (MI) within 6 months prior to first study drug administration 8. Patients with a known or suspected hypersensitivity to any of the components of OTS167. 9. Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). 10. Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38 degrees within 1 week prior to first study drug administration. 11. Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration. 12. Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug. 13. Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies. 14. Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements. 15. Any anti-neoplastic agent or monoclonal antibody therapy for the primary malignancy (standard or experimental) within 2 weeks prior to first study drug administration. 16. Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment. If acute symptoms of radiation have fully resolved, the extent and timing of radiotherapy for eligibility can be discussed between Investigator and Sponsor. 17. Patients requiring surgery for the primary or metastatic primary malignancy. 18. Herbal preparations or related over the counter (OTC) preparations/supplements containing herbal ingredients within 1 week prior to first study drug administration and during study. 19. Systemic hormonal therapy which is not related to breast cancer treatment (standard or experimental) within 1 week prior to first study drug administration and during study. The following therapies are allowed: -Hormonal therapy (e.g., Megace) for appetite stimulation -Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations -Oral replacement glucocorticoid therapy for adrenal insufficiency -Low-dose maintenance steroid therapy for other conditions (excluding steroid tapers for brain edema/metastases/radiation) -Hormonal contraceptive therapy (for WOCBP must be combined with non-hormonal contraceptive equivalent to a double-barrier method) 20. Any other investigational treatments during study. This includes participation in any medical device or therapeutic intervention clinical trials. Dose expansion Cohort for TNBC 21. Patients with only lesions that cannot be safely accessed for biopsy.\n"
+     ]
+    }
+   ],
+   "source": [
+    "# 値を直接取得して表示\n",
+    "print(basedf.loc[basedf['JRCT ID'] == 'jRCT2031230090', 'TargetWord'].values[0])\n",
+    "print(basedf.loc[basedf['JRCT ID'] == 'jRCT2031230090', 'TargetEnglish'].values[0])\n",
+    "print(basedf.loc[basedf['JRCT ID'] == 'jRCT2031230090', 'Exclusion Criteria'].values[0])\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 82,
+   "metadata": {},
+   "outputs": [
+    {
+     "name": "stderr",
+     "output_type": "stream",
+     "text": [
+      "/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
+      "  warnings.warn(\n"
+     ]
+    }
+   ],
+   "source": [
+    "# モデルのロード\n",
+    "model = SentenceTransformer('pritamdeka/S-PubMedBert-MS-MARCO')"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 89,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# クエリ\n",
+    "#query = \"Triple negative breast cancer\"\n",
+    "query = \"breast cancer\"\n",
+    "#query = \"glioma\"\n",
+    "threshold = 0.925\n",
+    "# クエリをベクトル化\n",
+    "query_vec = model.encode(query, convert_to_tensor=True)\n"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 90,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>31</th>\n",
+       "      <td>jRCT2061240081</td>\n",
+       "      <td>NCT06393374</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...</td>\n",
+       "      <td>トリプルネガティブ乳癌</td>\n",
+       "      <td>トリプルネガティブ乳癌</td>\n",
+       "      <td>Triple negative breast cancer</td>\n",
+       "      <td>術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Has centrally confirmed TNBC, as defined by t...</td>\n",
+       "      <td>-Has a known germline breast cancer gene (BRCA...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Arm 1: MK-2870 4mg/kg intravenous (IV) every ...</td>\n",
+       "      <td>[Triple Negative, Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>157</th>\n",
+       "      <td>jRCT2052240059</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>diagnostic purpose</td>\n",
+       "      <td>1. Histologically confirmed invasive breast ca...</td>\n",
+       "      <td>1. History of other malignancy within the last...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Omitting breast surgery after preoperative che...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>170</th>\n",
+       "      <td>jRCT2031240096</td>\n",
+       "      <td>NCT06380751</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>Advanced Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Adult females, pre/peri-menopausal and/or po...</td>\n",
+       "      <td>- Participants with history of MDS/AML or with...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental: Arm 1: saruparib (AZD5305) plus ...</td>\n",
+       "      <td>[Advanced Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>215</th>\n",
+       "      <td>jRCT2031230723</td>\n",
+       "      <td>NCT06112379</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be &gt;= 18 years at the time...</td>\n",
+       "      <td>1. As judged by the investigator, any evidence...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>240</th>\n",
+       "      <td>jRCT2061230102</td>\n",
+       "      <td>NCT06103864</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Histologically or cytologically documented loc...</td>\n",
+       "      <td>As judged by investigator, severe or uncontrol...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>307</th>\n",
+       "      <td>jRCT2061230074</td>\n",
+       "      <td>NCT05952557</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men; 18 years or more at the time ...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>351</th>\n",
+       "      <td>jRCT2031230279</td>\n",
+       "      <td>NCT05862285</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Eligible for continuing Roche IMP-based ther...</td>\n",
+       "      <td>- Meet any of the study treatment discontinuat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Ipatasertib: Ipatasertib will be administered ...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>388</th>\n",
+       "      <td>jRCT2031230109</td>\n",
+       "      <td>NCT05514054</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Neoplasms</td>\n",
+       "      <td>早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have a diagnosis of ER+, HER2- early-stage, r...</td>\n",
+       "      <td>-Have any evidence of metastatic disease (incl...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: Imlunestrant Administered orally. Other...</td>\n",
+       "      <td>[Breast Neoplasms]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>391</th>\n",
+       "      <td>jRCT2031230090</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...</td>\n",
+       "      <td>再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん</td>\n",
+       "      <td>再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん</td>\n",
+       "      <td>Relapsed/Refractory Locally Advanced or Metast...</td>\n",
+       "      <td>再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Dose Escalation and Dose Expansion Cohorts 1. ...</td>\n",
+       "      <td>Dose Escalation and Expansion Cohorts 1. Women...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>This is a Phase I dose escalation/expansion mu...</td>\n",
+       "      <td>[Relapsed/Refract, Y Locally Advanced, Metasta...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>392</th>\n",
+       "      <td>jRCT2031230096</td>\n",
+       "      <td>NCT05774951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men, greater than or equal to 18 y...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>402</th>\n",
+       "      <td>jRCT2061230009</td>\n",
+       "      <td>NCT05485766</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP...</td>\n",
+       "      <td>トリプルネガティブ乳がん</td>\n",
+       "      <td>トリプルネガティブ乳がん</td>\n",
+       "      <td>Triple Negative Breast Neoplasms</td>\n",
+       "      <td>術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1)Male/female subjects who are at least 18 yea...</td>\n",
+       "      <td>1) Subjects who has a positive urine pregnancy...</td>\n",
+       "      <td>18age old exceed</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Triple Negative Breast Cancer, Breast Neoplasm...</td>\n",
+       "      <td>Drug: Pembrolizumab 200 mg fixed dose, IV, eve...</td>\n",
+       "      <td>[Triple Negative, Breast Neoplasms]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>463</th>\n",
+       "      <td>jRCT2061220087</td>\n",
+       "      <td>NCT05629585</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Participant must be &gt;= 18 years at the time of...</td>\n",
+       "      <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>515</th>\n",
+       "      <td>jRCT2031220276</td>\n",
+       "      <td>NCT05307705</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have advanced breast cancer or another solid ...</td>\n",
+       "      <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>590</th>\n",
+       "      <td>jRCT2031210585</td>\n",
+       "      <td>NCT05123482</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...</td>\n",
+       "      <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>Breast Cancer, Biliary Tract Carcinoma, Ovaria...</td>\n",
+       "      <td>進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Age18 years or more - Relapsed/metastatic so...</td>\n",
+       "      <td>- Treatment with any of the following: 1. Nitr...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Sub-study1 AZD8205 Monotherapy AZD8205 is an a...</td>\n",
+       "      <td>[Breast Cancer, Biliary Tract Carcinoma, Ovari...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>593</th>\n",
+       "      <td>jRCT2031210560</td>\n",
+       "      <td>NCT05061823</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Participants who are currently enrolled in a...</td>\n",
+       "      <td>- Participants who are pregnant or currently i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Participants who are continuing treatment with...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>629</th>\n",
+       "      <td>jRCT2052210099</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>screening</td>\n",
+       "      <td>Breast cancer (including suspected) (1) One of...</td>\n",
+       "      <td>(1) There is trauma with bleeding on the breas...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The test using IGS-0001 will be performed twic...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>698</th>\n",
+       "      <td>jRCT2071200086</td>\n",
+       "      <td>NCT04640623</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG...</td>\n",
+       "      <td>膀胱癌</td>\n",
+       "      <td>膀胱癌</td>\n",
+       "      <td>Bladder Cancer</td>\n",
+       "      <td>試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Histologically confirmed diagnosis of persis...</td>\n",
+       "      <td>- Histologically confirmed, muscle-invasive, l...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-...</td>\n",
+       "      <td>[Bladder Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>18 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No JapicCTI No  \\\n",
+       "31   jRCT2061240081  NCT06393374         NaN   \n",
+       "157  jRCT2052240059          NaN         NaN   \n",
+       "170  jRCT2031240096  NCT06380751         NaN   \n",
+       "215  jRCT2031230723  NCT06112379         NaN   \n",
+       "240  jRCT2061230102  NCT06103864         NaN   \n",
+       "307  jRCT2061230074  NCT05952557         NaN   \n",
+       "351  jRCT2031230279  NCT05862285         NaN   \n",
+       "388  jRCT2031230109  NCT05514054         NaN   \n",
+       "391  jRCT2031230090          NaN         NaN   \n",
+       "392  jRCT2031230096  NCT05774951         NaN   \n",
+       "402  jRCT2061230009  NCT05485766         NaN   \n",
+       "463  jRCT2061220087  NCT05629585         NaN   \n",
+       "515  jRCT2031220276  NCT05307705         NaN   \n",
+       "590  jRCT2031210585  NCT05123482         NaN   \n",
+       "593  jRCT2031210560  NCT05061823         NaN   \n",
+       "629  jRCT2052210099          NaN         NaN   \n",
+       "698  jRCT2071200086  NCT04640623         NaN   \n",
+       "729  jRCT2031200057          NaN         NaN   \n",
+       "\n",
+       "                                                 Title  \\\n",
+       "31   術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...   \n",
+       "157  遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...   \n",
+       "170  本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...   \n",
+       "240  Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...   \n",
+       "307  根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...   \n",
+       "351  GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...   \n",
+       "388  EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...   \n",
+       "391  MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...   \n",
+       "392  根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...   \n",
+       "402  gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...   \n",
+       "515  PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...   \n",
+       "590  進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...   \n",
+       "593  複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...   \n",
+       "629  乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...   \n",
+       "698  膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG...   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験   \n",
+       "\n",
+       "                               TargetJ                             Target  \\\n",
+       "31                         トリプルネガティブ乳癌                        トリプルネガティブ乳癌   \n",
+       "157                                乳がん                                乳がん   \n",
+       "170                               進行乳癌                               進行乳癌   \n",
+       "215                                 乳癌                                 乳癌   \n",
+       "240                                 乳癌                                 乳癌   \n",
+       "307                          乳がん、早期乳がん                          乳がん、早期乳がん   \n",
+       "351                                  癌                                  癌   \n",
+       "388                                 乳癌                                 乳癌   \n",
+       "391  再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん  再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん   \n",
+       "392                          乳がん、早期乳がん                          乳がん、早期乳がん   \n",
+       "402                       トリプルネガティブ乳がん                       トリプルネガティブ乳がん   \n",
+       "463                                 乳癌                                 乳癌   \n",
+       "515                                乳がん                                乳がん   \n",
+       "590                   乳癌、胆道癌、卵巣癌、子宮内膜癌                   乳癌、胆道癌、卵巣癌、子宮内膜癌   \n",
+       "593                                固形癌                                固形癌   \n",
+       "629                                乳がん                                乳がん   \n",
+       "698                                膀胱癌                                膀胱癌   \n",
+       "729                                乳がん                                乳がん   \n",
+       "\n",
+       "                                         TargetEnglish  \\\n",
+       "31                       Triple negative breast cancer   \n",
+       "157                                      Breast cancer   \n",
+       "170                             Advanced Breast Cancer   \n",
+       "215                                      Breast Cancer   \n",
+       "240                                      Breast Cancer   \n",
+       "307                 Breast Cancer, Early Breast Cancer   \n",
+       "351                                             Cancer   \n",
+       "388                                   Breast Neoplasms   \n",
+       "391  Relapsed/Refractory Locally Advanced or Metast...   \n",
+       "392                 Breast Cancer, Early Breast Cancer   \n",
+       "402                   Triple Negative Breast Neoplasms   \n",
+       "463                                      Breast Cancer   \n",
+       "515                                      Breast Cancer   \n",
+       "590  Breast Cancer, Biliary Tract Carcinoma, Ovaria...   \n",
+       "593                                             Cancer   \n",
+       "629                                      Breast cancer   \n",
+       "698                                     Bladder Cancer   \n",
+       "729                                      Breast cancer   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "31   術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...        3   NaN  ...   \n",
+       "157  HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...        2   NaN  ...   \n",
+       "170                                          Treatment        3   NaN  ...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...        3   NaN  ...   \n",
+       "240  PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...        3   NaN  ...   \n",
+       "307                                          Treatment        3   NaN  ...   \n",
+       "351  本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...        3   NaN  ...   \n",
+       "388            早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験        3   NaN  ...   \n",
+       "391  再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...        1   NaN  ...   \n",
+       "392                                          Treatment        3   NaN  ...   \n",
+       "402  術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク...        2   NaN  ...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...        3   NaN  ...   \n",
+       "515  LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...        1   NaN  ...   \n",
+       "590            進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究      1-2   NaN  ...   \n",
+       "593  本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...        3   NaN  ...   \n",
+       "629  本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...        2   NaN  ...   \n",
+       "698  試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT...        2   NaN  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "\n",
+       "                purpose                                 Inclusion Criteria  \\\n",
+       "31    treatment purpose  -Has centrally confirmed TNBC, as defined by t...   \n",
+       "157  diagnostic purpose  1. Histologically confirmed invasive breast ca...   \n",
+       "170   treatment purpose  - Adult females, pre/peri-menopausal and/or po...   \n",
+       "215   treatment purpose  1. Participant must be >= 18 years at the time...   \n",
+       "240   treatment purpose  Histologically or cytologically documented loc...   \n",
+       "307   treatment purpose  - Women and Men; 18 years or more at the time ...   \n",
+       "351   treatment purpose  - Eligible for continuing Roche IMP-based ther...   \n",
+       "388   treatment purpose  -Have a diagnosis of ER+, HER2- early-stage, r...   \n",
+       "391   treatment purpose  Dose Escalation and Dose Expansion Cohorts 1. ...   \n",
+       "392   treatment purpose  - Women and Men, greater than or equal to 18 y...   \n",
+       "402   treatment purpose  1)Male/female subjects who are at least 18 yea...   \n",
+       "463   treatment purpose  Participant must be >= 18 years at the time of...   \n",
+       "515   treatment purpose  -Have advanced breast cancer or another solid ...   \n",
+       "590   treatment purpose  - Age18 years or more - Relapsed/metastatic so...   \n",
+       "593   treatment purpose  - Participants who are currently enrolled in a...   \n",
+       "629           screening  Breast cancer (including suspected) (1) One of...   \n",
+       "698   treatment purpose  - Histologically confirmed diagnosis of persis...   \n",
+       "729   treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "\n",
+       "                                    Exclusion Criteria       Age Minimum  \\\n",
+       "31   -Has a known germline breast cancer gene (BRCA...    18age old over   \n",
+       "157  1. History of other malignancy within the last...    20age old over   \n",
+       "170  - Participants with history of MDS/AML or with...    18age old over   \n",
+       "215  1. As judged by the investigator, any evidence...    18age old over   \n",
+       "240  As judged by investigator, severe or uncontrol...    18age old over   \n",
+       "307  - Inoperable locally advanced or metastatic br...    18age old over   \n",
+       "351  - Meet any of the study treatment discontinuat...    18age old over   \n",
+       "388  -Have any evidence of metastatic disease (incl...    18age old over   \n",
+       "391  Dose Escalation and Expansion Cohorts 1. Women...    18age old over   \n",
+       "392  - Inoperable locally advanced or metastatic br...    18age old over   \n",
+       "402  1) Subjects who has a positive urine pregnancy...  18age old exceed   \n",
+       "463  Stage IV (metastatic) TNBC. History of prior i...    18age old over   \n",
+       "515  -Medical Conditions -Colorectal cancer -Endome...    18age old over   \n",
+       "590  - Treatment with any of the following: 1. Nitr...    18age old over   \n",
+       "593  - Participants who are pregnant or currently i...    18age old over   \n",
+       "629  (1) There is trauma with bleeding on the breas...    20age old over   \n",
+       "698  - Histologically confirmed, muscle-invasive, l...    18age old over   \n",
+       "729  1)Patients correspond to either of the followi...    20age old over   \n",
+       "\n",
+       "          Age Maximum  Gender Discontinuation Criteria  \\\n",
+       "31           No limit    Both                      NaN   \n",
+       "157          No limit  Female                      NaN   \n",
+       "170          No limit    Both                      NaN   \n",
+       "215          No limit    Both                      NaN   \n",
+       "240          No limit    Both                      NaN   \n",
+       "307          No limit     NaN                      NaN   \n",
+       "351          No limit    Both                      NaN   \n",
+       "388          No limit    Both                      NaN   \n",
+       "391          No limit  Female                      NaN   \n",
+       "392          No limit    Both                      NaN   \n",
+       "402          No limit    Both                      NaN   \n",
+       "463  130age old under    Both                      NaN   \n",
+       "515          No limit    Both                      NaN   \n",
+       "590          No limit    Both                      NaN   \n",
+       "593          No limit    Both                      NaN   \n",
+       "629          No limit  Female                      NaN   \n",
+       "698          No limit    Both                      NaN   \n",
+       "729          No limit  Female                      NaN   \n",
+       "\n",
+       "                                               Keyword  \\\n",
+       "31                                                 NaN   \n",
+       "157                                                NaN   \n",
+       "170                                                NaN   \n",
+       "215                                                NaN   \n",
+       "240                                                NaN   \n",
+       "307                                                NaN   \n",
+       "351                                                NaN   \n",
+       "388                                                NaN   \n",
+       "391                                                NaN   \n",
+       "392                                                NaN   \n",
+       "402  Triple Negative Breast Cancer, Breast Neoplasm...   \n",
+       "463                                                NaN   \n",
+       "515                                                NaN   \n",
+       "590                                                NaN   \n",
+       "593                                                NaN   \n",
+       "629                                                NaN   \n",
+       "698                                                NaN   \n",
+       "729                                      Breast cancer   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "31   -Arm 1: MK-2870 4mg/kg intravenous (IV) every ...   \n",
+       "157  Omitting breast surgery after preoperative che...   \n",
+       "170  Experimental: Arm 1: saruparib (AZD5305) plus ...   \n",
+       "215  - Experimental arm: Dato-DXd plus durvalumab n...   \n",
+       "240  Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...   \n",
+       "307  arm A: continue with SoC ET as directed by inv...   \n",
+       "351  Ipatasertib: Ipatasertib will be administered ...   \n",
+       "388  -Drug: Imlunestrant Administered orally. Other...   \n",
+       "391  This is a Phase I dose escalation/expansion mu...   \n",
+       "392  arm A: continue with SoC ET as directed by inv...   \n",
+       "402  Drug: Pembrolizumab 200 mg fixed dose, IV, eve...   \n",
+       "463  Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...   \n",
+       "515  -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...   \n",
+       "590  Sub-study1 AZD8205 Monotherapy AZD8205 is an a...   \n",
+       "593  Participants who are continuing treatment with...   \n",
+       "629  The test using IGS-0001 will be performed twic...   \n",
+       "698  TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "\n",
+       "                                            TargetWord  \n",
+       "31                    [Triple Negative, Breast Cancer]  \n",
+       "157                                    [Breast Cancer]  \n",
+       "170                           [Advanced Breast Cancer]  \n",
+       "215                                    [Breast Cancer]  \n",
+       "240                                    [Breast Cancer]  \n",
+       "307               [Breast Cancer, Early Breast Cancer]  \n",
+       "351                                           [Cancer]  \n",
+       "388                                 [Breast Neoplasms]  \n",
+       "391  [Relapsed/Refract, Y Locally Advanced, Metasta...  \n",
+       "392               [Breast Cancer, Early Breast Cancer]  \n",
+       "402                [Triple Negative, Breast Neoplasms]  \n",
+       "463                                    [Breast Cancer]  \n",
+       "515                                    [Breast Cancer]  \n",
+       "590  [Breast Cancer, Biliary Tract Carcinoma, Ovari...  \n",
+       "593                                           [Cancer]  \n",
+       "629                                    [Breast Cancer]  \n",
+       "698                                   [Bladder Cancer]  \n",
+       "729                                    [Breast Cancer]  \n",
+       "\n",
+       "[18 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 90,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# ターゲットリスト全体を処理\n",
+    "matched_indices = []\n",
+    "target_vecs_list = []\n",
+    "cosine_scores_list = []\n",
+    "for idx, target_words in enumerate(basedf['TargetWord']):\n",
+    "    # ターゲット内の各単語をベクトル化\n",
+    "    target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
+    "    # コサイン類似度を計算\n",
+    "    cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
+    "    target_vecs_list.append(target_vecs)\n",
+    "    cosine_scores_list.append(cosine_scores)\n",
+    "    # 閾値を超えるか確認\n",
+    "    if (cosine_scores >= threshold).any():  # いずれかが閾値を超えている場合\n",
+    "        matched_indices.append(idx)\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df = basedf.iloc[matched_indices]\n",
+    "matched_df"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 92,
+   "metadata": {},
+   "outputs": [
+    {
+     "ename": "TypeError",
+     "evalue": "list indices must be integers or slices, not list",
+     "output_type": "error",
+     "traceback": [
+      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
+      "\u001b[0;31mTypeError\u001b[0m                                 Traceback (most recent call last)",
+      "Cell \u001b[0;32mIn[92], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mcosine_scores_list\u001b[49m\u001b[43m \u001b[49m\u001b[43m[\u001b[49m\u001b[43mmatched_indices\u001b[49m\u001b[43m]\u001b[49m\n",
+      "\u001b[0;31mTypeError\u001b[0m: list indices must be integers or slices, not list"
+     ]
+    }
+   ],
+   "source": [
+    "cosine_scores_list [matched_indices]"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": null,
+   "metadata": {},
+   "outputs": [],
+   "source": []
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 86,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>31</th>\n",
+       "      <td>jRCT2061240081</td>\n",
+       "      <td>NCT06393374</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...</td>\n",
+       "      <td>トリプルネガティブ乳癌</td>\n",
+       "      <td>トリプルネガティブ乳癌</td>\n",
+       "      <td>Triple negative breast cancer</td>\n",
+       "      <td>術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Has centrally confirmed TNBC, as defined by t...</td>\n",
+       "      <td>-Has a known germline breast cancer gene (BRCA...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Arm 1: MK-2870 4mg/kg intravenous (IV) every ...</td>\n",
+       "      <td>[Triple Negative, Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>157</th>\n",
+       "      <td>jRCT2052240059</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>diagnostic purpose</td>\n",
+       "      <td>1. Histologically confirmed invasive breast ca...</td>\n",
+       "      <td>1. History of other malignancy within the last...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Omitting breast surgery after preoperative che...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>215</th>\n",
+       "      <td>jRCT2031230723</td>\n",
+       "      <td>NCT06112379</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be &gt;= 18 years at the time...</td>\n",
+       "      <td>1. As judged by the investigator, any evidence...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>240</th>\n",
+       "      <td>jRCT2061230102</td>\n",
+       "      <td>NCT06103864</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Histologically or cytologically documented loc...</td>\n",
+       "      <td>As judged by investigator, severe or uncontrol...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>307</th>\n",
+       "      <td>jRCT2061230074</td>\n",
+       "      <td>NCT05952557</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men; 18 years or more at the time ...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>388</th>\n",
+       "      <td>jRCT2031230109</td>\n",
+       "      <td>NCT05514054</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Neoplasms</td>\n",
+       "      <td>早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have a diagnosis of ER+, HER2- early-stage, r...</td>\n",
+       "      <td>-Have any evidence of metastatic disease (incl...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: Imlunestrant Administered orally. Other...</td>\n",
+       "      <td>[Breast Neoplasms]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>391</th>\n",
+       "      <td>jRCT2031230090</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...</td>\n",
+       "      <td>再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん</td>\n",
+       "      <td>再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん</td>\n",
+       "      <td>Relapsed/Refractory Locally Advanced or Metast...</td>\n",
+       "      <td>再発・難治性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Dose Escalation and Dose Expansion Cohorts 1. ...</td>\n",
+       "      <td>Dose Escalation and Expansion Cohorts 1. Women...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>This is a Phase I dose escalation/expansion mu...</td>\n",
+       "      <td>[Relapsed/Refract, Y Locally Advanced, Metasta...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>392</th>\n",
+       "      <td>jRCT2031230096</td>\n",
+       "      <td>NCT05774951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men, greater than or equal to 18 y...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>402</th>\n",
+       "      <td>jRCT2061230009</td>\n",
+       "      <td>NCT05485766</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP...</td>\n",
+       "      <td>トリプルネガティブ乳がん</td>\n",
+       "      <td>トリプルネガティブ乳がん</td>\n",
+       "      <td>Triple Negative Breast Neoplasms</td>\n",
+       "      <td>術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1)Male/female subjects who are at least 18 yea...</td>\n",
+       "      <td>1) Subjects who has a positive urine pregnancy...</td>\n",
+       "      <td>18age old exceed</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Triple Negative Breast Cancer, Breast Neoplasm...</td>\n",
+       "      <td>Drug: Pembrolizumab 200 mg fixed dose, IV, eve...</td>\n",
+       "      <td>[Triple Negative, Breast Neoplasms]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>463</th>\n",
+       "      <td>jRCT2061220087</td>\n",
+       "      <td>NCT05629585</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Participant must be &gt;= 18 years at the time of...</td>\n",
+       "      <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>515</th>\n",
+       "      <td>jRCT2031220276</td>\n",
+       "      <td>NCT05307705</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have advanced breast cancer or another solid ...</td>\n",
+       "      <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>590</th>\n",
+       "      <td>jRCT2031210585</td>\n",
+       "      <td>NCT05123482</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...</td>\n",
+       "      <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>乳癌、胆道癌、卵巣癌、子宮内膜癌</td>\n",
+       "      <td>Breast Cancer, Biliary Tract Carcinoma, Ovaria...</td>\n",
+       "      <td>進行又は転移性固形がんに対する治療法候���としての新規化合物AZD8205の研究</td>\n",
+       "      <td>1-2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Age18 years or more - Relapsed/metastatic so...</td>\n",
+       "      <td>- Treatment with any of the following: 1. Nitr...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Sub-study1 AZD8205 Monotherapy AZD8205 is an a...</td>\n",
+       "      <td>[Breast Cancer, Biliary Tract Carcinoma, Ovari...</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>629</th>\n",
+       "      <td>jRCT2052210099</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>screening</td>\n",
+       "      <td>Breast cancer (including suspected) (1) One of...</td>\n",
+       "      <td>(1) There is trauma with bleeding on the breas...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The test using IGS-0001 will be performed twic...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>14 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No JapicCTI No  \\\n",
+       "31   jRCT2061240081  NCT06393374         NaN   \n",
+       "157  jRCT2052240059          NaN         NaN   \n",
+       "215  jRCT2031230723  NCT06112379         NaN   \n",
+       "240  jRCT2061230102  NCT06103864         NaN   \n",
+       "307  jRCT2061230074  NCT05952557         NaN   \n",
+       "388  jRCT2031230109  NCT05514054         NaN   \n",
+       "391  jRCT2031230090          NaN         NaN   \n",
+       "392  jRCT2031230096  NCT05774951         NaN   \n",
+       "402  jRCT2061230009  NCT05485766         NaN   \n",
+       "463  jRCT2061220087  NCT05629585         NaN   \n",
+       "515  jRCT2031220276  NCT05307705         NaN   \n",
+       "590  jRCT2031210585  NCT05123482         NaN   \n",
+       "629  jRCT2052210099          NaN         NaN   \n",
+       "729  jRCT2031200057          NaN         NaN   \n",
+       "\n",
+       "                                                 Title  \\\n",
+       "31   術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...   \n",
+       "157  遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...   \n",
+       "240  Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...   \n",
+       "307  根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...   \n",
+       "388  EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...   \n",
+       "391  MELK阻害剤OTS167POにおける転移性・進行性乳がん患者を対象とした安全性、忍容性およ...   \n",
+       "392  根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...   \n",
+       "402  gBRCA1/2遺伝子変異を有するトリプルネガティブ原発乳がんに対するプラチナ製剤、PARP...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...   \n",
+       "515  PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...   \n",
+       "590  進行又は転移性固形がん患者を対象としたAZD8205の単独療法及び他の抗がん剤との併用療法に...   \n",
+       "629  乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験   \n",
+       "\n",
+       "                               TargetJ                             Target  \\\n",
+       "31                         トリプルネガティブ乳癌                        トリプルネガティブ乳癌   \n",
+       "157                                乳がん                                乳がん   \n",
+       "215                                 乳癌                                 乳癌   \n",
+       "240                                 乳癌                                 乳癌   \n",
+       "307                          乳がん、早期乳がん                          乳がん、早期乳がん   \n",
+       "388                                 乳癌                                 乳癌   \n",
+       "391  再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん  再発・難治性の局所進行性・転移性乳がん及びトリプルネガティブ乳がん   \n",
+       "392                          乳がん、早期乳がん                          乳がん、早期乳がん   \n",
+       "402                       トリプルネガティブ乳がん                       トリプルネガティブ乳がん   \n",
+       "463                                 乳癌                                 乳癌   \n",
+       "515                                乳がん                                乳がん   \n",
+       "590                   乳癌、胆道癌、卵巣癌、子宮内膜癌                   乳癌、胆道癌、卵巣癌、子宮内膜癌   \n",
+       "629                                乳がん                                乳がん   \n",
+       "729                                乳がん                                乳がん   \n",
+       "\n",
+       "                                         TargetEnglish  \\\n",
+       "31                       Triple negative breast cancer   \n",
+       "157                                      Breast cancer   \n",
+       "215                                      Breast Cancer   \n",
+       "240                                      Breast Cancer   \n",
+       "307                 Breast Cancer, Early Breast Cancer   \n",
+       "388                                   Breast Neoplasms   \n",
+       "391  Relapsed/Refractory Locally Advanced or Metast...   \n",
+       "392                 Breast Cancer, Early Breast Cancer   \n",
+       "402                   Triple Negative Breast Neoplasms   \n",
+       "463                                      Breast Cancer   \n",
+       "515                                      Breast Cancer   \n",
+       "590  Breast Cancer, Biliary Tract Carcinoma, Ovaria...   \n",
+       "629                                      Breast cancer   \n",
+       "729                                      Breast cancer   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "31   術前薬物療法後の手術時に病理学的完全奏効を達成していないトリプルネガティブ乳癌患者を対象に、...        3   NaN  ...   \n",
+       "157  HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...        2   NaN  ...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...        3   NaN  ...   \n",
+       "240  PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...        3   NaN  ...   \n",
+       "307                                          Treatment        3   NaN  ...   \n",
+       "388            早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験        3   NaN  ...   \n",
+       "391  再発・難��性の局所進行性または転移性乳がん患者に対して、OTS167を経口カプセルで投与する...        1   NaN  ...   \n",
+       "392                                          Treatment        3   NaN  ...   \n",
+       "402  術前療法としてgBRCA変異陽性手術可能または局所進行TNBCに対してペムブロリズマブ+パク...        2   NaN  ...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...        3   NaN  ...   \n",
+       "515  LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...        1   NaN  ...   \n",
+       "590            進行又は転移性固形がんに対する治療法候補としての新規化合物AZD8205の研究      1-2   NaN  ...   \n",
+       "629  本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...        2   NaN  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "\n",
+       "                purpose                                 Inclusion Criteria  \\\n",
+       "31    treatment purpose  -Has centrally confirmed TNBC, as defined by t...   \n",
+       "157  diagnostic purpose  1. Histologically confirmed invasive breast ca...   \n",
+       "215   treatment purpose  1. Participant must be >= 18 years at the time...   \n",
+       "240   treatment purpose  Histologically or cytologically documented loc...   \n",
+       "307   treatment purpose  - Women and Men; 18 years or more at the time ...   \n",
+       "388   treatment purpose  -Have a diagnosis of ER+, HER2- early-stage, r...   \n",
+       "391   treatment purpose  Dose Escalation and Dose Expansion Cohorts 1. ...   \n",
+       "392   treatment purpose  - Women and Men, greater than or equal to 18 y...   \n",
+       "402   treatment purpose  1)Male/female subjects who are at least 18 yea...   \n",
+       "463   treatment purpose  Participant must be >= 18 years at the time of...   \n",
+       "515   treatment purpose  -Have advanced breast cancer or another solid ...   \n",
+       "590   treatment purpose  - Age18 years or more - Relapsed/metastatic so...   \n",
+       "629           screening  Breast cancer (including suspected) (1) One of...   \n",
+       "729   treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "\n",
+       "                                    Exclusion Criteria       Age Minimum  \\\n",
+       "31   -Has a known germline breast cancer gene (BRCA...    18age old over   \n",
+       "157  1. History of other malignancy within the last...    20age old over   \n",
+       "215  1. As judged by the investigator, any evidence...    18age old over   \n",
+       "240  As judged by investigator, severe or uncontrol...    18age old over   \n",
+       "307  - Inoperable locally advanced or metastatic br...    18age old over   \n",
+       "388  -Have any evidence of metastatic disease (incl...    18age old over   \n",
+       "391  Dose Escalation and Expansion Cohorts 1. Women...    18age old over   \n",
+       "392  - Inoperable locally advanced or metastatic br...    18age old over   \n",
+       "402  1) Subjects who has a positive urine pregnancy...  18age old exceed   \n",
+       "463  Stage IV (metastatic) TNBC. History of prior i...    18age old over   \n",
+       "515  -Medical Conditions -Colorectal cancer -Endome...    18age old over   \n",
+       "590  - Treatment with any of the following: 1. Nitr...    18age old over   \n",
+       "629  (1) There is trauma with bleeding on the breas...    20age old over   \n",
+       "729  1)Patients correspond to either of the followi...    20age old over   \n",
+       "\n",
+       "          Age Maximum  Gender Discontinuation Criteria  \\\n",
+       "31           No limit    Both                      NaN   \n",
+       "157          No limit  Female                      NaN   \n",
+       "215          No limit    Both                      NaN   \n",
+       "240          No limit    Both                      NaN   \n",
+       "307          No limit     NaN                      NaN   \n",
+       "388          No limit    Both                      NaN   \n",
+       "391          No limit  Female                      NaN   \n",
+       "392          No limit    Both                      NaN   \n",
+       "402          No limit    Both                      NaN   \n",
+       "463  130age old under    Both                      NaN   \n",
+       "515          No limit    Both                      NaN   \n",
+       "590          No limit    Both                      NaN   \n",
+       "629          No limit  Female                      NaN   \n",
+       "729          No limit  Female                      NaN   \n",
+       "\n",
+       "                                               Keyword  \\\n",
+       "31                                                 NaN   \n",
+       "157                                                NaN   \n",
+       "215                                                NaN   \n",
+       "240                                                NaN   \n",
+       "307                                                NaN   \n",
+       "388                                                NaN   \n",
+       "391                                                NaN   \n",
+       "392                                                NaN   \n",
+       "402  Triple Negative Breast Cancer, Breast Neoplasm...   \n",
+       "463                                                NaN   \n",
+       "515                                                NaN   \n",
+       "590                                                NaN   \n",
+       "629                                                NaN   \n",
+       "729                                      Breast cancer   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "31   -Arm 1: MK-2870 4mg/kg intravenous (IV) every ...   \n",
+       "157  Omitting breast surgery after preoperative che...   \n",
+       "215  - Experimental arm: Dato-DXd plus durvalumab n...   \n",
+       "240  Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...   \n",
+       "307  arm A: continue with SoC ET as directed by inv...   \n",
+       "388  -Drug: Imlunestrant Administered orally. Other...   \n",
+       "391  This is a Phase I dose escalation/expansion mu...   \n",
+       "392  arm A: continue with SoC ET as directed by inv...   \n",
+       "402  Drug: Pembrolizumab 200 mg fixed dose, IV, eve...   \n",
+       "463  Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...   \n",
+       "515  -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...   \n",
+       "590  Sub-study1 AZD8205 Monotherapy AZD8205 is an a...   \n",
+       "629  The test using IGS-0001 will be performed twic...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "\n",
+       "                                            TargetWord  \n",
+       "31                    [Triple Negative, Breast Cancer]  \n",
+       "157                                    [Breast Cancer]  \n",
+       "215                                    [Breast Cancer]  \n",
+       "240                                    [Breast Cancer]  \n",
+       "307               [Breast Cancer, Early Breast Cancer]  \n",
+       "388                                 [Breast Neoplasms]  \n",
+       "391  [Relapsed/Refract, Y Locally Advanced, Metasta...  \n",
+       "392               [Breast Cancer, Early Breast Cancer]  \n",
+       "402                [Triple Negative, Breast Neoplasms]  \n",
+       "463                                    [Breast Cancer]  \n",
+       "515                                    [Breast Cancer]  \n",
+       "590  [Breast Cancer, Biliary Tract Carcinoma, Ovari...  \n",
+       "629                                    [Breast Cancer]  \n",
+       "729                                    [Breast Cancer]  \n",
+       "\n",
+       "[14 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 86,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "# ターゲットリスト全体を処理\n",
+    "matched_indices = []\n",
+    "target_vecs_list = []\n",
+    "cosine_scores_list = []\n",
+    "for idx, target_words in enumerate(basedf['TargetWord']):\n",
+    "    # ターゲット内の各単語をベクトル化\n",
+    "    target_vecs = model.encode(target_words, convert_to_tensor=True)\n",
+    "    # コサイン類似度を計算\n",
+    "    cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()\n",
+    "    target_vecs_list.append(target_vecs)\n",
+    "    cosine_scores_list.append(cosine_scores)\n",
+    "    # 閾値を超えるか確認\n",
+    "    if (cosine_scores >= threshold).any():  # いずれかが閾値を超えている場合\n",
+    "        matched_indices.append(idx)\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df = basedf.iloc[matched_indices]\n",
+    "matched_df"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 14,
+   "metadata": {},
+   "outputs": [],
+   "source": [
+    "# 全データのターゲット列をベクトル化\n",
+    "target_list = basedf['TargetEnglish'].tolist()\n",
+    "target_vecs = model.encode(target_list, convert_to_tensor=True)\n",
+    "# コサイン類似度を計算\n",
+    "cosine_scores = util.cos_sim(query_vec, target_vecs).squeeze()"
+   ]
+  },
+  {
+   "cell_type": "code",
+   "execution_count": 15,
+   "metadata": {},
+   "outputs": [
+    {
+     "data": {
+      "text/html": [
+       "<div>\n",
+       "<style scoped>\n",
+       "    .dataframe tbody tr th:only-of-type {\n",
+       "        vertical-align: middle;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe tbody tr th {\n",
+       "        vertical-align: top;\n",
+       "    }\n",
+       "\n",
+       "    .dataframe thead th {\n",
+       "        text-align: right;\n",
+       "    }\n",
+       "</style>\n",
+       "<table border=\"1\" class=\"dataframe\">\n",
+       "  <thead>\n",
+       "    <tr style=\"text-align: right;\">\n",
+       "      <th></th>\n",
+       "      <th>JRCT ID</th>\n",
+       "      <th>NCT No</th>\n",
+       "      <th>JapicCTI No</th>\n",
+       "      <th>Title</th>\n",
+       "      <th>TargetJ</th>\n",
+       "      <th>Target</th>\n",
+       "      <th>TargetEnglish</th>\n",
+       "      <th>研究・治験の目的</th>\n",
+       "      <th>試験等のフェーズ</th>\n",
+       "      <th>試験の種類</th>\n",
+       "      <th>...</th>\n",
+       "      <th>purpose</th>\n",
+       "      <th>Inclusion Criteria</th>\n",
+       "      <th>Exclusion Criteria</th>\n",
+       "      <th>Age Minimum</th>\n",
+       "      <th>Age Maximum</th>\n",
+       "      <th>Gender</th>\n",
+       "      <th>Discontinuation Criteria</th>\n",
+       "      <th>Keyword</th>\n",
+       "      <th>Intervention(s)</th>\n",
+       "      <th>TargetWord</th>\n",
+       "    </tr>\n",
+       "  </thead>\n",
+       "  <tbody>\n",
+       "    <tr>\n",
+       "      <th>157</th>\n",
+       "      <td>jRCT2052240059</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>diagnostic purpose</td>\n",
+       "      <td>1. Histologically confirmed invasive breast ca...</td>\n",
+       "      <td>1. History of other malignancy within the last...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Omitting breast surgery after preoperative che...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>170</th>\n",
+       "      <td>jRCT2031240096</td>\n",
+       "      <td>NCT06380751</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>進行乳癌</td>\n",
+       "      <td>Advanced Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Adult females, pre/peri-menopausal and/or po...</td>\n",
+       "      <td>- Participants with history of MDS/AML or with...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Experimental: Arm 1: saruparib (AZD5305) plus ...</td>\n",
+       "      <td>[Advanced Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>215</th>\n",
+       "      <td>jRCT2031230723</td>\n",
+       "      <td>NCT06112379</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>1. Participant must be &gt;= 18 years at the time...</td>\n",
+       "      <td>1. As judged by the investigator, any evidence...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Experimental arm: Dato-DXd plus durvalumab n...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>240</th>\n",
+       "      <td>jRCT2061230102</td>\n",
+       "      <td>NCT06103864</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Histologically or cytologically documented loc...</td>\n",
+       "      <td>As judged by investigator, severe or uncontrol...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>307</th>\n",
+       "      <td>jRCT2061230074</td>\n",
+       "      <td>NCT05952557</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men; 18 years or more at the time ...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>342</th>\n",
+       "      <td>jRCT2051230094</td>\n",
+       "      <td>NCT05794906</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>前立腺癌の高リスク生化学的再発（BCR）患者を対象としたアンドロゲン遮断療法（ADT）を併用...</td>\n",
+       "      <td>前立腺癌</td>\n",
+       "      <td>前立腺癌</td>\n",
+       "      <td>prostate cancer</td>\n",
+       "      <td>BAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Histologically or cytologically confirmed ad...</td>\n",
+       "      <td>- Pathological finding consistent with small c...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Male</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Drug: Darolutamide (BAY1841788, Nubeqa) Coated...</td>\n",
+       "      <td>[prostate cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>351</th>\n",
+       "      <td>jRCT2031230279</td>\n",
+       "      <td>NCT05862285</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Eligible for continuing Roche IMP-based ther...</td>\n",
+       "      <td>- Meet any of the study treatment discontinuat...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Ipatasertib: Ipatasertib will be administered ...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>388</th>\n",
+       "      <td>jRCT2031230109</td>\n",
+       "      <td>NCT05514054</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Neoplasms</td>\n",
+       "      <td>早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have a diagnosis of ER+, HER2- early-stage, r...</td>\n",
+       "      <td>-Have any evidence of metastatic disease (incl...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: Imlunestrant Administered orally. Other...</td>\n",
+       "      <td>[Breast Neoplasms]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>392</th>\n",
+       "      <td>jRCT2031230096</td>\n",
+       "      <td>NCT05774951</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>乳がん、早期乳がん</td>\n",
+       "      <td>Breast Cancer, Early Breast Cancer</td>\n",
+       "      <td>Treatment</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Women and Men, greater than or equal to 18 y...</td>\n",
+       "      <td>- Inoperable locally advanced or metastatic br...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>arm A: continue with SoC ET as directed by inv...</td>\n",
+       "      <td>[Breast Cancer, Early Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>463</th>\n",
+       "      <td>jRCT2061220087</td>\n",
+       "      <td>NCT05629585</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>乳癌</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>Participant must be &gt;= 18 years at the time of...</td>\n",
+       "      <td>Stage IV (metastatic) TNBC. History of prior i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>130age old under</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>515</th>\n",
+       "      <td>jRCT2031220276</td>\n",
+       "      <td>NCT05307705</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast Cancer</td>\n",
+       "      <td>LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>-Have advanced breast cancer or another solid ...</td>\n",
+       "      <td>-Medical Conditions -Colorectal cancer -Endome...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>-Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...</td>\n",
+       "      <td>[Breast Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>593</th>\n",
+       "      <td>jRCT2031210560</td>\n",
+       "      <td>NCT05061823</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>固形癌</td>\n",
+       "      <td>Cancer</td>\n",
+       "      <td>本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...</td>\n",
+       "      <td>3</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Participants who are currently enrolled in a...</td>\n",
+       "      <td>- Participants who are pregnant or currently i...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Participants who are continuing treatment with...</td>\n",
+       "      <td>[Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>600</th>\n",
+       "      <td>jRCT2041210123</td>\n",
+       "      <td>NCT05114746</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>進行性PSMA陽性転移性去勢抵抗性前立腺がん（mCRPC）を有する患者を対象に177Lu-P...</td>\n",
+       "      <td>前立腺癌</td>\n",
+       "      <td>前立腺癌</td>\n",
+       "      <td>Prostate Cancer</td>\n",
+       "      <td>本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- ECOG performance status: 1. Post-taxane popu...</td>\n",
+       "      <td>- Previous treatment with any of the following...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Male</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Radiation: 177Lu-PSMA-617 administered intrave...</td>\n",
+       "      <td>[Prostate Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>629</th>\n",
+       "      <td>jRCT2052210099</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>screening</td>\n",
+       "      <td>Breast cancer (including suspected) (1) One of...</td>\n",
+       "      <td>(1) There is trauma with bleeding on the breas...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>The test using IGS-0001 will be performed twic...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>691</th>\n",
+       "      <td>jRCT2031200384</td>\n",
+       "      <td>NCT04221542</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性...</td>\n",
+       "      <td>前立腺がん</td>\n",
+       "      <td>前立腺がん</td>\n",
+       "      <td>Prostate Cancer</td>\n",
+       "      <td>成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Parts 1, 2, and 5: Participants with histolo...</td>\n",
+       "      <td>- Pathological finding consistent with pure sm...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Male</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>- Experimental: Part 1: AMG 509 Intravenous (I...</td>\n",
+       "      <td>[Prostate Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>698</th>\n",
+       "      <td>jRCT2071200086</td>\n",
+       "      <td>NCT04640623</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG...</td>\n",
+       "      <td>膀胱癌</td>\n",
+       "      <td>膀胱癌</td>\n",
+       "      <td>Bladder Cancer</td>\n",
+       "      <td>試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT...</td>\n",
+       "      <td>2</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>- Histologically confirmed diagnosis of persis...</td>\n",
+       "      <td>- Histologically confirmed, muscle-invasive, l...</td>\n",
+       "      <td>18age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Both</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-...</td>\n",
+       "      <td>[Bladder Cancer]</td>\n",
+       "    </tr>\n",
+       "    <tr>\n",
+       "      <th>729</th>\n",
+       "      <td>jRCT2031200057</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>乳がん</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...</td>\n",
+       "      <td>1</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>...</td>\n",
+       "      <td>treatment purpose</td>\n",
+       "      <td>&lt;Disease Characteristics&gt; 1)Patients with inop...</td>\n",
+       "      <td>1)Patients correspond to either of the followi...</td>\n",
+       "      <td>20age old over</td>\n",
+       "      <td>No limit</td>\n",
+       "      <td>Female</td>\n",
+       "      <td>NaN</td>\n",
+       "      <td>Breast cancer</td>\n",
+       "      <td>For the target tumor, the dose settled at each...</td>\n",
+       "      <td>[Breast cancer]</td>\n",
+       "    </tr>\n",
+       "  </tbody>\n",
+       "</table>\n",
+       "<p>17 rows × 40 columns</p>\n",
+       "</div>"
+      ],
+      "text/plain": [
+       "            JRCT ID       NCT No JapicCTI No  \\\n",
+       "157  jRCT2052240059          NaN         NaN   \n",
+       "170  jRCT2031240096  NCT06380751         NaN   \n",
+       "215  jRCT2031230723  NCT06112379         NaN   \n",
+       "240  jRCT2061230102  NCT06103864         NaN   \n",
+       "307  jRCT2061230074  NCT05952557         NaN   \n",
+       "342  jRCT2051230094  NCT05794906         NaN   \n",
+       "351  jRCT2031230279  NCT05862285         NaN   \n",
+       "388  jRCT2031230109  NCT05514054         NaN   \n",
+       "392  jRCT2031230096  NCT05774951         NaN   \n",
+       "463  jRCT2061220087  NCT05629585         NaN   \n",
+       "515  jRCT2031220276  NCT05307705         NaN   \n",
+       "593  jRCT2031210560  NCT05061823         NaN   \n",
+       "600  jRCT2041210123  NCT05114746         NaN   \n",
+       "629  jRCT2052210099          NaN         NaN   \n",
+       "691  jRCT2031200384  NCT04221542         NaN   \n",
+       "698  jRCT2071200086  NCT04640623         NaN   \n",
+       "729  jRCT2031200057          NaN         NaN   \n",
+       "\n",
+       "                                                 Title    TargetJ     Target  \\\n",
+       "157  遺伝子HSD17B4高メチル化を有するHER2陽性ER陰性乳癌における非手術療法の有用性を評...        乳がん        乳がん   \n",
+       "170  本治験の主要目的は、BRCA1、BRCA2 又は PALB2 変異を有し、HR 陽性、HER...       進行乳癌       進行乳癌   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現／HER2陰性乳癌の成人患者を対象として、...         乳癌         乳癌   \n",
+       "240  Programmed death-ligand（PD-L1）陽性の局所再発手術不能又は転移性...         乳癌         乳癌   \n",
+       "307  根治的局所治療（化学療法の併用または非併用）を受けて疾患の兆候のない、再発リスクが中間～高リ...  乳がん、早期乳がん  乳がん、早期乳がん   \n",
+       "342  前立腺癌の高リスク生化学的再発（BCR）患者を対象としたアンドロゲン遮断療法（ADT）を併用...       前立腺癌       前立腺癌   \n",
+       "351  GENENTECH社及び／又はF.HOFFMANN-LA ROCHE LTDが依頼した試験に...          癌          癌   \n",
+       "388  EMBER-4：2～5年間の術後内分泌療法による前治療歴を有する再発高リスクのER+、HER...         乳癌         乳癌   \n",
+       "392  根治的局所領域療法（化学療法の併用または非併用）および標準補助内分泌療法（ET）を少なくとも...  乳がん、早期乳がん  乳がん、早期乳がん   \n",
+       "463  術前薬物療法後の外科的切除時に乳房及び／又は腋窩リンパ節に浸潤性残存病変を有するステージI～...         乳癌         乳癌   \n",
+       "515  PIK3CA H1047R変異を有する進行乳がん患者及びその他の固形がん患者を対象としたLO...        乳がん        乳がん   \n",
+       "593  複数のBintrafusp alfa（M7824）臨床試験の被験者を対象に長期データを収集す...        固形癌        固形癌   \n",
+       "600  進行性PSMA陽性転移性去勢抵抗性前立腺がん（mCRPC）を有する患者を対象に177Lu-P...       前立腺癌       前立腺癌   \n",
+       "629  乳がんを有する成人女性及び健康成人女性を対象とした乳房用マイクロ波画像診断装置IGS-000...        乳がん        乳がん   \n",
+       "691  転移性去勢抵抗性前立腺がん患者を対象としたAMG 509の安全性、忍容性、薬物動態及び有効性...      前立腺がん      前立腺がん   \n",
+       "698  膀胱全摘除術に不適格である，又は膀胱全摘除術を選択しなかった，カルメット・ゲラン桿菌（BCG...        膀胱癌        膀胱癌   \n",
+       "729      治療抵抗性乳がんを対象としたTDM-812の腫瘍内投与法の安全性評価を目的とした第I相試験        乳がん        乳がん   \n",
+       "\n",
+       "                          TargetEnglish  \\\n",
+       "157                       Breast cancer   \n",
+       "170              Advanced Breast Cancer   \n",
+       "215                       Breast Cancer   \n",
+       "240                       Breast Cancer   \n",
+       "307  Breast Cancer, Early Breast Cancer   \n",
+       "342                     prostate cancer   \n",
+       "351                              Cancer   \n",
+       "388                    Breast Neoplasms   \n",
+       "392  Breast Cancer, Early Breast Cancer   \n",
+       "463                       Breast Cancer   \n",
+       "515                       Breast Cancer   \n",
+       "593                              Cancer   \n",
+       "600                     Prostate Cancer   \n",
+       "629                       Breast cancer   \n",
+       "691                     Prostate Cancer   \n",
+       "698                      Bladder Cancer   \n",
+       "729                       Breast cancer   \n",
+       "\n",
+       "                                              研究・治験の目的 試験等のフェーズ 試験の種類  ...  \\\n",
+       "157  HSD17B4高メチル化(HSD17B4 hypermethylation:HH)を有するH...        2   NaN  ...   \n",
+       "170                                          Treatment        3   NaN  ...   \n",
+       "215  未治療のトリプルネガティブ又はホルモン受容体低発現/HER2陰性乳癌の成人患者を対象として、...        3   NaN  ...   \n",
+       "240  PD-L1陽性の局所再発手術不能または転移性TNBC患者を対象に、デュルバルマブ併用または非...        3   NaN  ...   \n",
+       "307                                          Treatment        3   NaN  ...   \n",
+       "342  BAY 1841788(darolutamide)とADTの24ヵ月間併用投与によって、プラ...        3   NaN  ...   \n",
+       "351  本継続投与試験の目的は,親治験から移行する時点でまだ治験治療を受けており,その地域でその治療...        3   NaN  ...   \n",
+       "388            早期乳癌患者を対象としたimlunestrantと標準的な内分泌療法の比較試験        3   NaN  ...   \n",
+       "392                                          Treatment        3   NaN  ...   \n",
+       "463  術前薬物療法後の外科的切除時に乳房および/または腋窩リンパ節に浸潤性残存病変を有するI~II...        3   NaN  ...   \n",
+       "515  LOXO-783 の単独投与及び他の抗がん剤との併用投与における 第 2 相試験の推奨用量、...        1   NaN  ...   \n",
+       "593  本治験は、実施中のbintrafusp alfaの親試験( (NCT02517398, NC...        3   NaN  ...   \n",
+       "600  本治験の目的は、進行性PSMA陽性mCRPCの日本人患者に177Lu-PSMA-617を投与...        2   NaN  ...   \n",
+       "629  本治験の目的は,乳がん又はその疑いのある者,並びに乳がん又はその疑いがない者を対象に乳房画像...        2   NaN  ...   \n",
+       "691  成人被験者のAMG 509の安全性及び忍容性を評価し、最大耐量(MTD)又は第II 相推奨用...        1   NaN  ...   \n",
+       "698  試験の目的は、高グレードTa又はT1乳頭状癌の併発の有無を問わない上皮内癌(CIS)患者にT...        2   NaN  ...   \n",
+       "729  TDM-812の腫瘍内投与の安全性および忍容性を評価し、今後の臨床評価に用いる腫瘍内投与にお...        1   NaN  ...   \n",
+       "\n",
+       "                purpose                                 Inclusion Criteria  \\\n",
+       "157  diagnostic purpose  1. Histologically confirmed invasive breast ca...   \n",
+       "170   treatment purpose  - Adult females, pre/peri-menopausal and/or po...   \n",
+       "215   treatment purpose  1. Participant must be >= 18 years at the time...   \n",
+       "240   treatment purpose  Histologically or cytologically documented loc...   \n",
+       "307   treatment purpose  - Women and Men; 18 years or more at the time ...   \n",
+       "342   treatment purpose  - Histologically or cytologically confirmed ad...   \n",
+       "351   treatment purpose  - Eligible for continuing Roche IMP-based ther...   \n",
+       "388   treatment purpose  -Have a diagnosis of ER+, HER2- early-stage, r...   \n",
+       "392   treatment purpose  - Women and Men, greater than or equal to 18 y...   \n",
+       "463   treatment purpose  Participant must be >= 18 years at the time of...   \n",
+       "515   treatment purpose  -Have advanced breast cancer or another solid ...   \n",
+       "593   treatment purpose  - Participants who are currently enrolled in a...   \n",
+       "600   treatment purpose  - ECOG performance status: 1. Post-taxane popu...   \n",
+       "629           screening  Breast cancer (including suspected) (1) One of...   \n",
+       "691   treatment purpose  - Parts 1, 2, and 5: Participants with histolo...   \n",
+       "698   treatment purpose  - Histologically confirmed diagnosis of persis...   \n",
+       "729   treatment purpose  <Disease Characteristics> 1)Patients with inop...   \n",
+       "\n",
+       "                                    Exclusion Criteria     Age Minimum  \\\n",
+       "157  1. History of other malignancy within the last...  20age old over   \n",
+       "170  - Participants with history of MDS/AML or with...  18age old over   \n",
+       "215  1. As judged by the investigator, any evidence...  18age old over   \n",
+       "240  As judged by investigator, severe or uncontrol...  18age old over   \n",
+       "307  - Inoperable locally advanced or metastatic br...  18age old over   \n",
+       "342  - Pathological finding consistent with small c...  18age old over   \n",
+       "351  - Meet any of the study treatment discontinuat...  18age old over   \n",
+       "388  -Have any evidence of metastatic disease (incl...  18age old over   \n",
+       "392  - Inoperable locally advanced or metastatic br...  18age old over   \n",
+       "463  Stage IV (metastatic) TNBC. History of prior i...  18age old over   \n",
+       "515  -Medical Conditions -Colorectal cancer -Endome...  18age old over   \n",
+       "593  - Participants who are pregnant or currently i...  18age old over   \n",
+       "600  - Previous treatment with any of the following...  20age old over   \n",
+       "629  (1) There is trauma with bleeding on the breas...  20age old over   \n",
+       "691  - Pathological finding consistent with pure sm...  18age old over   \n",
+       "698  - Histologically confirmed, muscle-invasive, l...  18age old over   \n",
+       "729  1)Patients correspond to either of the followi...  20age old over   \n",
+       "\n",
+       "          Age Maximum  Gender Discontinuation Criteria        Keyword  \\\n",
+       "157          No limit  Female                      NaN            NaN   \n",
+       "170          No limit    Both                      NaN            NaN   \n",
+       "215          No limit    Both                      NaN            NaN   \n",
+       "240          No limit    Both                      NaN            NaN   \n",
+       "307          No limit     NaN                      NaN            NaN   \n",
+       "342          No limit    Male                      NaN            NaN   \n",
+       "351          No limit    Both                      NaN            NaN   \n",
+       "388          No limit    Both                      NaN            NaN   \n",
+       "392          No limit    Both                      NaN            NaN   \n",
+       "463  130age old under    Both                      NaN            NaN   \n",
+       "515          No limit    Both                      NaN            NaN   \n",
+       "593          No limit    Both                      NaN            NaN   \n",
+       "600          No limit    Male                      NaN            NaN   \n",
+       "629          No limit  Female                      NaN            NaN   \n",
+       "691          No limit    Male                      NaN            NaN   \n",
+       "698          No limit    Both                      NaN            NaN   \n",
+       "729          No limit  Female                      NaN  Breast cancer   \n",
+       "\n",
+       "                                       Intervention(s)  \\\n",
+       "157  Omitting breast surgery after preoperative che...   \n",
+       "170  Experimental: Arm 1: saruparib (AZD5305) plus ...   \n",
+       "215  - Experimental arm: Dato-DXd plus durvalumab n...   \n",
+       "240  Arm 1: Dato-DXd + durvalumab Arm 2: Investigat...   \n",
+       "307  arm A: continue with SoC ET as directed by inv...   \n",
+       "342  Drug: Darolutamide (BAY1841788, Nubeqa) Coated...   \n",
+       "351  Ipatasertib: Ipatasertib will be administered ...   \n",
+       "388  -Drug: Imlunestrant Administered orally. Other...   \n",
+       "392  arm A: continue with SoC ET as directed by inv...   \n",
+       "463  Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Du...   \n",
+       "515  -Drug: LOXO-783 Oral Other Name: LY3849524 -Dr...   \n",
+       "593  Participants who are continuing treatment with...   \n",
+       "600  Radiation: 177Lu-PSMA-617 administered intrave...   \n",
+       "629  The test using IGS-0001 will be performed twic...   \n",
+       "691  - Experimental: Part 1: AMG 509 Intravenous (I...   \n",
+       "698  TAR-200 Cohort 1: TAR-200 and Cetrelimab: TAR-...   \n",
+       "729  For the target tumor, the dose settled at each...   \n",
+       "\n",
+       "                               TargetWord  \n",
+       "157                       [Breast cancer]  \n",
+       "170              [Advanced Breast Cancer]  \n",
+       "215                       [Breast Cancer]  \n",
+       "240                       [Breast Cancer]  \n",
+       "307  [Breast Cancer, Early Breast Cancer]  \n",
+       "342                     [prostate cancer]  \n",
+       "351                              [Cancer]  \n",
+       "388                    [Breast Neoplasms]  \n",
+       "392  [Breast Cancer, Early Breast Cancer]  \n",
+       "463                       [Breast Cancer]  \n",
+       "515                       [Breast Cancer]  \n",
+       "593                              [Cancer]  \n",
+       "600                     [Prostate Cancer]  \n",
+       "629                       [Breast cancer]  \n",
+       "691                     [Prostate Cancer]  \n",
+       "698                      [Bladder Cancer]  \n",
+       "729                       [Breast cancer]  \n",
+       "\n",
+       "[17 rows x 40 columns]"
+      ]
+     },
+     "execution_count": 15,
+     "metadata": {},
+     "output_type": "execute_result"
+    }
+   ],
+   "source": [
+    "matched_indices_d = (cosine_scores >= threshold).nonzero().tolist()\n",
+    "# 入れ子リストをフラットなリストに変換\n",
+    "flat_indices_d = [idx[0] for idx in matched_indices_d]\n",
+    "\n",
+    "# 抽出\n",
+    "matched_df_d = basedf.iloc[flat_indices_d]\n",
+    "matched_df_d\n"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": []
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": [
+    "\n"
+   ]
+  },
+  {
+   "cell_type": "markdown",
+   "metadata": {},
+   "source": []
+  }
+ ],
+ "metadata": {
+  "kernelspec": {
+   "display_name": "gradio",
+   "language": "python",
+   "name": "python3"
+  },
+  "language_info": {
+   "codemirror_mode": {
+    "name": "ipython",
+    "version": 3
+   },
+   "file_extension": ".py",
+   "mimetype": "text/x-python",
+   "name": "python",
+   "nbconvert_exporter": "python",
+   "pygments_lexer": "ipython3",
+   "version": "3.12.3"
+  }
+ },
+ "nbformat": 4,
+ "nbformat_minor": 2
+}